Table 2.
Randomized controlled trials of gonadotropin-releasing hormone agonists
| Study (trial) | Enrolled (control) | Evaluable (control) | Type of GnRHa | Disease | Follow-up (yr) | Primary outcome | No. of pregnancies (%) (GnRHa/control) | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Zhong et al. (2019) [87] | 98 (47) | 96 (45) | G 3.6 mg | Breast | 1.25 | POF | - | 0.002 | |
| Zhang et al. (2018) [86] | 216 (108) | 170 (78) | G 3.75 mg, L 11.25 mg | Breast | 4.7 | POF | - | NS | |
| Leonard et al. (2017) (OPTION) [85] | 227 (121) | 202 (107) | G 3.6 mg | Breast | 5 | POV | 9 (9)/6 (6) | 0.015 | |
| Demeestere et al. (2016) [84] | 129 (64) | 67 (35) | T 11.25 mg | Lymphoma | 5.33 | POF | 17 (53.1)/14 (42.8) | NS | |
| Moore et al. (2015) (POEMS) [83] | 257 (131) | 218 (113) | G 3.6 mg | Breast | 4.1 | POV | 22 (21)/12 (11) | 0.04 | |
| Lambertini et al. (2015) (PROMISE-GIM6) [82] | 281 (133) | 281 (133) | T 3.75 mg | Breast | 7.3 | POV | 8 (5)/3 (2) | 0.006 | |
| Karimi-Zarchi et al. (2014) [81] | 42 (21) | 42 (21) | D 3.75 mg | Breast | 0.5 | ROM | - | <0.001 | |
| Elgindy et al. (2013) [80] | 100 (50) | 70 (37) | T 3.75 mg | Breast | 1 | ROM | 1 (4)/1 (4) | NS | |
| Song et al. (2013) [79] | 220 (110) | 183 (94) | L | Breast | 1 | POV | - | 0.04 | |
| Munster et al. (2012) [78] | 49 (22) | 47 (21) | T | Breast | 1.6 | POV | 0/2 (10) | NS | |
| Gerber et al. (2011) (ZORO) [77] | 61 (31) | 60 (30) | G 3.6 mg | Breast | 4 | ROM | 1 (3)/1 (3) | NS | |
| Behringer et al. (2010) [76] | 23 (12) | 20 (10) | G 3.6 mg | Lymphoma | 2.1 | POF | - | NR | |
| Sverrisdottir et al. (2009) [75] | 285 | 260 (123) | G 3.6 mg | Breast | ~3.0 | ROM | - | 0.006 | |
| Badawy et al. (2009) [74] | 80 (40) | 78 (39) | G 3.6 mg | Breast | 0.7 | ROM | - | 0.001 | |
| Gilani et al. (2007) [73] | 30 (15) | 30 (15) | D3.75 mg | Ovary | 0.5 | FSH, LH, E2 | - | NR | |
| Giuseppe et al. (2007) [72] | 29 (15) | 29 (15) | T 3.25 mg, 11.25 mg | Lymphoma | 3.59 | ROM | 0 (14)/2 (15) | NR | |
| Waxman et al. (1987) [8] | 18 (10) | 18 (10) | B (nasal) | Lymphoma | 2 | ROM | - | NR |
GnRHa, gonadotrophin-releasing hormone agonist; G, goserelin; L, leuprorelin; T, triptorelin; D, Diphereline; B, buserelin; POF, premature ovarian failure; POV, preservation of ovarian function; ROM, resumption of menses; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; OPTION, Ovarian Protection Trial In Premenopausal Breast Cancer Patients; POEMS, Prevention of Early Menopause Study; PROMISE-GIM6, Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients-Gruppo Italiano Mammella 6; ZORO, Zoladex Rescue of Ovarian function; NS, not significant; NR, not reported.